Friday, 16 October 2026European Markets
ExploreSearch
ViaNews EU
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· December 27, 2025

XRP’s Historic December 2017 Surge Revisited—Could 2025 Set Up a Similar Move?

View original at finance.yahoo.com
XRP’s Historic December 2017 Surge Revisited—Could 2025 Set Up a Similar Move? Tsikhanovich Alena / Shutterstock.com Quick Read XRP rallied 1,200% in 6 weeks (December 2017): $0.25 to $3.30 driven by retail FOMO, exchange listings, Bitcoin hitting $20K…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • 2017 had zero institutional participation vs measured allocations in 2025; no regulatory clarity vs SEC settlement; pure speculation vs banks using ODL ($1.3B quarterly)

    80% confidence

  • Over 1.35 billion XRP tokens have been removed from circulation into long-term custody, representing 45% less supply available for sale

    80% confidence

  • Social media was flooded with 'XRP to $10' predictions during the 2017 rally

    80% confidence

  • Steady 50-100% gains could push XRP to $3-4 by mid-2026, or price could remain range-bound between $1.80-$2.50 as institutions accumulate slowly

    80% confidence

  • A repeat of the 1,200% rally is possible in December 2025 if catalysts, sentiment, adoption, and structure align

    80% confidence

  • 2025 replaces retail mania with institutional firepower: $1.1B ETF inflows in 4 weeks, SEC settlement August 2025, RLUSD at $1B market cap

    80% confidence

  • XRP rallied 1,200% in 6 weeks from December 2017, driven by retail FOMO, exchange listings, and Bitcoin hitting $20K

    80% confidence

Data points we hold from this source

XRP · circulating supply reduction1.35 billion_tokens
XRP · stock price range1.80-2.20 USD
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com